Menu
← Oncology Approval Tracker
FDA DECISION ·
Inqovi + venetoclax
oral decitabine and cedazuridine with venetoclax · Taiho Oncology
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Newly diagnosed AML in adults aged 75 or older or with comorbidities that preclude intensive induction chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The regimen offers an oral decitabine combination for a population with age or comorbidity constraints. Oral administration shifts some burden to adherence and outpatient monitoring.
What research teams should watch
Plan medication review, adherence support and timely lab follow-up. Keep the response findings in context as coming from a single-arm study.
PRIMARY RECORDS